A randomized phase II study of BB-10010: A variant of human macrophage inflammatory protein-1α for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer

British Journal of Haematology

Volumn 99, Issue 4, 1997, Pages 888-895

  Bernstein, Steven H ^a   Eaves, Connie J ^b   Herzig, Roger ^c   Fay, Joseph ^d   Lynch, Joseph ^e   Phillips, Gordon L ^f   Christiansen, Neal ^a   Reece, Donna ^f   Ericson, Solveig ^e   Stephan, Margaret ^a   Kovalsky, Matthew ^g   Hawkins, Kim ^g   Rasmussen, Henrik ^g   Devos, Arien ^g   Herzig, Geoffrey P ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e WEST VIRGINIA UNIVERSITY   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g British Biotech Inc   (United States)

Author keywords

Chemotherapy; Haemopoiosis; MIP 1 ; Mucositis; Progenitors

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; LYMPHOSARCOMA; MALE; MUCOSA INFLAMMATION; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINUSITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 6844249420     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.4913294.x     Document Type: Article

References (21)

1. Brown, R.A., Herzig, R.H., Wolff, S.N., Frei-Lahr, D., Pineiro, L., Bolwell, B.J., Lowder, J.N., Harden, E.A., Hande, K.R. & Herzig, G.P. (1990) High dose etoposide and cyclophosphamide without hone marrow transplantation for resistant hematologic malignancy. Blood, 76, 473-479.
2. Cashman, J.D., Eaves, A.C. & Eaves, C.J. (1997) Selective inhibition of the cycling activity of intermediate types of human progenitors regenerated in NOD/SCID mice. (Abstract). Experimental Hematology, in press.
3. Dunlop, D.J., Wright, E.G., Lorimore, S., Graham, G.J., Holyoake, T., Kerr, D.J., Wolpe, S.D. & Pragnell, I.B. (1992) Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP-1a in vivo. Blood, 79, 2221-2225.
4. Eaves, C.J., Cashman, J.D., Wolpe, S.D. & Eaves, A.C. (1993) Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflummatory protein-1α, an inhibitor of primitive normal hematopoietic cells. Proceedings of the National Academy of Sciences of the United States of America, 90, 12015-12019.
5. Emermann, J.T. & Eaves, C.J. (1994) Lack of effect of hematopoietic growth factors on human breast epithelial cell growth in serumfree primary culture. Bone Marrow Transplantation, 13, 285-291.
6. Ferrajoli, A., Talpaz, M., Zip, T.F., Hirsch-Ginsberg, C., Estey, E., Wolpe, S.D. & Estrov, Z. (1994) Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-α. Leukemia, 8, 798-805.
7. Gordon, M.S., McCaskill-Stevens, W.J., Broxmeyer, H.E., Battiato, L.A., Harrison-Mann, B., Kovalsky, M., Rasmussen, H.S. & Sledge, G.W. (1996) A phase I trial of subcutaneous (SC) BB-10010 in breast cancer patients (PTS) receiving high-dose cyclophosphamide (C). (Abstract). Proceedings of the American Society of Clinical Oncology, 15, 273.
8. Graham, G.J. & Pragnell, I. (1992) SCI/MIP-1α: a potent stem cell inhibitor with potential roles in development. Developmental Biology, 151, 377-581.
9. Graham, G.J., Wright, E.G., Hewick, R., Wolpe, S.D., Wilkie, N., Donaldson, D., Lorimore, S. & Pragnell, I.B. (1990) Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature, 344, 442-444.
10. Hogge, D.E., Lansdorp, P.M., Reid, D., Gerhard, B. & Eaves, C.J. (1996) Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produced human steel factor, interleukin-3 and granulocyte colony-stimulating factor. Blood, 88, 3765-3773.
11. Hunter, M.G., Bawden, L., Brotherton, D., Craig, S., Cribbes, S., Czaplewski, L.G., Dexter, T.M., Drummond, A.H., Gearing, A.H., Heyworth, C.M., Lord, B.I., McCourt, M., Varley, P.G., Wood, L.M., Edwards, R.M. & Lewis, P.J. (1995) BB-10010: an active variant of human macrophage inflammatory protein-1α with improved pharmaceutical properties. Blood, 86, 4400-4408.
12. Klingemann, H.G., Deal, H., Reid, D. & Eaves, C.J. (1993) Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Experimental Hematology, 21, 1263-1270.
13. Lord, B.I., Dexter, T.M., Clements, J.M., Hunter, M.A. & Gearing, A.J.H. (1992) Macrophage-inflammatory protein protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in-vivo. Blood, 79, 2605-2609.
14. Lord, B.I., Woolford, L.B., Wood, L.M., Czaplewski, L.G., McCourt, M., Hunter, M.G. & Edwards, R.M. (1995) Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1α. Blood, 85, 3412-3415.
15. Pawlick, R., Eaves, C. & Humphries, R.K. (1996) Evidence of both ontogeny and transplant dose-regulated expansion of hematopoietic stem cells in vivo. Blood, 88, 2852-2858.
16. Petzer, A.L., Eaves, C.J., Lansdorp, P.M., Ponchio, L., Barnett, M.J. & Eaves, A.C. (1996) Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood, 88, 2162-2171.
17. Podestà, M., Piaggio, G., Frassoni, F., Pitto, A., Mordini, N., Bregante, S., Valeriani, A. & Bacigalupo, A. (1997) Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 19, 1011-1017.
18. Ponchio, L., Conneally, E. & Eaves, C. (1995) Quantitation of the quiescent fraction of long term culture-initiating cells (LTC-IC) in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro. Blood, 86, 3314-3321.
19. Schubert, M.M., Williams, B.E., Lloid, M.E., Donaldson, G. & Chapko, M.K. (1992) Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Cancer, 69, 2469-2477.
20. Sutherland, H.J., Eaves, A.C. & Eaves, C.J. (1991) Quantitative assays for human hemopoietic progenitor cells. Bone Marrow Processing and Purging: a Practical Guide (ed. by A. P. Gee), p. 155. CRC Press. Boca Raton, Florida.
21. Wolpe, S.D. & Cerami, A. (1989) Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. Federation of American Societies for Experimental Biology Journal 3, 2656-2673.